(Q36338763)

English

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

19

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Alessandra Ferrajoli

9

object named as

Alessandra Ferrajoli

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

6

object named as

Stefan Faderl

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

18

object named as

Zeev Estrov

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Srdan Verstovsek

11

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

William G Wierda

10

object named as

William G Wierda

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

16

object named as

Elias Jabbour

1 reference

Europe PubMed Central

13 August 2017

PMC publication ID

Jorge Eduardo Cortes

3

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

13 August 2017

PMC publication ID

Rebecca S Garris

5

object named as

Rebecca Garris

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Richard E Champlin

12

object named as

Richard Champlin

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Partow Kebriaei

13

object named as

Partow Kebriaei

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

15

object named as

Xuelin Huang

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Michael E Rytting

8

object named as

Michael E Rytting

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Deborah A McCue

14

object named as

Deborah A McCue

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Guillermo Garcia-Manero

17

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

7

object named as

Jan A Burger

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Susan M O'Brien

2

object named as

Susan M O'Brien

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

author name string

Deborah M Thomas

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

language of work or name

0 references

publication date

26 August 2015

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

121

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

23

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

4158-4164

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

30 September 2017

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

30 September 2017

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

30 September 2017

Ponatinib in refractory Philadelphia chromosome-positive leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

30 September 2017

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

30 September 2017

Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

30 September 2017

Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

30 September 2017

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

30 September 2017

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

30 September 2017

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

30 September 2017

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

30 September 2017

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

30 September 2017

Advances in the management of Ph-positive ALL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

30 September 2017

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

30 September 2017

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

29 June 2018

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

22 September 2018

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

22 September 2018

Philadelphia-positive acute lymphoblastic leukemia--is bone marrow transplant still necessary?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

22 September 2018

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

22 September 2018

The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666803

22 September 2018

Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29646

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29646

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29646

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.29646

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36338763&oldid=1858460894"